Cardinal Health (CAH) recently announced the ongoing construction of a new distribution center in Fort Worth, TX, to support its at-Home Solutions business.Similar to the distribution centers recently launched in South Carolina and Ohio, this new facility incorporates advanced robotics and automation technology. These innovations enhance efficiency by supporting employees in tasks such as picking, packing, and shipping while also improving speed and workplace safety.Likely Trend of CAH Stock Following the N ...

Key Takeaways Industry and Company Overview 1. **Company**: Cardinal Health, Inc. (NYSE:CAH) 2. **Event**: J.P. Morgan Healthcare Conference 3. **Date**: January 14, 2025 4. **Participants**: - Aaron Alt - CFO - Jason Hollar - CEO - Lisa Gill - JPMorgan [1] Core Views and Arguments 1. **Bullish on Healthcare Industry**: Cardinal Health is highly optimistic about the healthcare industry, particularly within their niche and the secular trends that uniquely benefit them. 2. **Positive Guidance Update**: The company issued an 8-K with a positive update to their guidance, which CEO Jason Hollar will discuss further. 3. **Earnings Release**: Cardinal Health is scheduled to release earnings on January 30, 2025, at which time they will provide further updates on their business. 4. **Forward-Looking Statements**: Both Aaron Alt and Jason Hollar will be making forward-looking statements during the call, with references to their SEC filings for a full list of risks and opportunities. [2][3][4]

New facility will be outfitted with latest robotics and automation technologies DUBLIN, Ohio, Jan. 14, 2025 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced construction is underway on a new distribution center in Fort Worth, Texas, which will support its at-Home Solutions business, a leading medical supplies provider that serves more than 5 million patients annually in the United States. The new 340,000 square foot distribution center will consolidate its two existing warehouses into one larger facili ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Cardinal Health (CAH) . This company, which is in the Zacks Medical - Dental Supplies industry, shows potential for another earnings beat.This prescription drug distributor has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters w ...

Cardinal Health Inc. (CAH) is well-poised for growth, given its long-term supply agreements, diversified product portfolio and strong quarterly earnings. However, the possibility of losing a major customer remains a risk.Shares of this Zacks Rank #2 (Buy) company have risen 12.7% in the past year compared with the industry’s 1.5% growth. The S&P 500 Index has gained 26.2% in the same time frame. CAH, with a market capitalization of $28.62 billion, is a nationwide drug distributor and service provider to pha ...

Dublin, Dec. 30, 2024 (GLOBE NEWSWIRE) -- The "Canada Personal Protective Equipment Market Outlook to 2033 - Gloves, Gowns, Masks, Shoe Covers and Others" report has been added to ResearchAndMarkets.com's offering.The "Canada Personal Protective Equipment Market Outlook to 2033" is a comprehensive databook report, covering key market data on the Canada Personal Protective Equipment market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments - Examination ...

The most recent trading session ended with Cardinal Health (CAH) standing at $118.83, reflecting a +0.41% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 1.1%. Meanwhile, the Dow gained 0.91%, and the Nasdaq, a tech-heavy index, added 1.35%.Shares of the prescription drug distributor have depreciated by 2.81% over the course of the past month, outperforming the Medical sector's loss of 3.78% and lagging the S&P 500's gain of 0.22%.Investors will be eagerly watchi ...

DUBLIN, Ohio, Dec. 19, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2025 on January 30, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern. To access the webcast and corresponding slide presentation, visit Cardinal Health's Investor Relations page. No access code is required. Presentation slides and a webcast replay will be available on ...

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are underva ...

Core Viewpoint - Cardinal Health Inc. is positioned for growth through an acquisition-driven strategy, a diversified product portfolio, and a strong pharmaceutical segment, despite facing inflationary pressures [1][2]. Financial Performance - Cardinal Health's shares have increased by 24.3% year-to-date, outperforming the industry gain of 4.8% and the S&P 500 Index's increase of 27.1% [1]. - The company has a market capitalization of $29.83 billion and an earnings yield of 6.3%, higher than the industry's 4.6% [2]. - Cardinal Health anticipates a 10.2% improvement in earnings over the next five years [2]. Pharmaceutical Segment Insights - The pharmaceutical segment is a key growth driver, with products and services including pharmaceutical distribution and specialty services [4]. - In Q4 fiscal 2024, total revenues declined by 4.3% year-over-year to $52.28 billion, with pharmaceutical revenues decreasing by 5% to $48 billion. Excluding the OptumRx impact, pharmaceutical sales increased by 16% [5]. - The company expects a 4-6% decline in pharmaceutical revenues for fiscal 2025, primarily due to the OptumRx contract expiration, which represents a $39 billion revenue headwind [6]. Recent Acquisitions - Cardinal Health has recently acquired Advanced Diabetes Supply Group and a majority stake in GI Alliance, which are expected to enhance revenues and profits in the first 12 months post-acquisition [6][8]. - These acquisitions align with Cardinal Health's strategy to support the growing diabetic patient population and expand its multi-specialty platform [7]. Q1 Fiscal 2024 Results - The company reported strong Q1 results, with global medical products and distribution revenues totaling $3.1 billion, a 3% year-over-year increase [10]. - Gross profit rose by 9.1% year-over-year, and operating income improved significantly to $568 million from an operating loss of $32 million in the previous year [11]. Notable Developments - Cardinal Health launched the Kendall SCD SmartFlow Compression System, aimed at preventing venous thromboembolism and enhancing patient care [12]. - The company entered a multi-year exclusive agreement with T2 Biosystems to distribute rapid diagnostics for sepsis detection [13]. Revenue Estimates - The Zacks Consensus Estimate for fiscal 2025 revenues is $219 billion, indicating a 3.5% decline from the previous year, while adjusted earnings per share are expected to increase by 3.9% to $7.82 [17].